Preliminary Program: SATURDAY MAY 20
8 a.m.-Noon
CME Courses 1-3
9 a.m.-4 p.m.
CME Courses 4-9
10 a.m.-5 p.m.
APA Member Center Opens
Publishers' Bookfair Opens
Registration/Course Enrollment Opens
12:30 p.m.-3:30 p.m.
Industry-Supported Symposia
IS1. New Augmentation Strategies in Depression for Better Outcomes
Supported by GlaxoSmithKline
Polypharmacy in Depression: How Often is it Used and Why? Joshua A. Israel, M.D. | |||||
“How To” Augmentation Strategies in Resistant Depression Charles DeBattista, M.D. | |||||
When Does Polypharmacy Lead to Higher Remission Rates? Jonathan E. Alpert, M.D. | |||||
Adding Psychotherapy: Pearls for Improved Outcomes Amy Farabaugh, Ph.D. | |||||
Pharmacological Antidotes for Antidepressant-Induced Side Effects Anita H. Clayton, M.D. | |||||
IS2. Strategies for Maintaining Wellness in Patients With Bipolar Disorder: Moving Beyond Efficacy to EffectivenessSupported by Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.
Impact of Misdiagnosis of Bipolar Disorder on Patient Outcomes Claudia F. Baldassano, M.D. | |||||
Brains and Genes: Implications for the Treatment of Bipolar Disorder Kiki D. Chang, M.D. | |||||
Evaluation of Clinical Trials in Bipolar Disease Gary S. Sachs, M.D. | |||||
Impact of Patient Satisfaction With Treatment on Treatment Outcomes Holly A. Swartz, M.D. | |||||
IS3. Navigating the Maze: Understanding Methods, Results, and Risks in Psychiatric ResearchSupported by Forest Laboratories, Inc.
Assessing Statistical and Clinical Significance in Medical Research David J. Kupfer, M.D. | |||||
All Risk Factors Are Not Created Equal: The Importance of Defining and Interpreting Risk on Medical Decision Making and Patient Care Helena C. Kraemer, Ph.D. | |||||
Determining Efficacy: Sound Clinical Trial Design and Interpretation Cornelius Katona, M.D. | |||||
Treating Depression in Children and Adolescents: What's a Clinician to Do? Jeff Q. Bostic, M.D. | |||||
How to Treat in the Absence of Scientific Evidence: A Focus on Anxiety Disorders in the Elderly Eric J. Lenze, M.D. | |||||
IS4. Bridging Sleep Science and Public PolicySupported by Takeda Pharmaceuticals North America, Inc.
The Science of Sleep David N. Neubauer, M.D. | |||||
Adolescents and School Start Times: The Intersection of Research and Public Policy R. Robert Auger, M.D. | |||||
Shiftwork, Sleep, and Performance Gregory Belenky, M.D. | |||||
Medical Education and Resident Duty Hours Phyllis C. Zee, M.D. | |||||
Insomnia and Public Policy Daniel J. Buysse, M.D. | |||||
1 p.m.-5 p.m.
CME Courses 10-14
6 p.m.-9 p.m.
Industry-Supported Symposia
IS5. Mania in Special PopulationsSupported by Shire US, Inc.
Recent Developments in the Treatment of Mania Robert M.A. Hirschfeld, M.D. | |||||
Recognition and Management of Child and Adolescent Bipolar Disorder Karen D. Wagner, M.D. | |||||
Bipolar Disorders in Women: Clinical and Metabolic Correlates Natalie L. Rasgon, M.D. | |||||
Bipolar Disorder in the Older Patient Brent P. Forester, M.D. | |||||
Recognizing Bipolar Disorder in African Americans William B. Lawson, M.D. | |||||
IS6. Verging on Reality: Emergent Therapeutic Approaches for SchizophreniaSupported by Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.
Functional Genomics and the Therapeutic Effects of Antipsychotics Anil K. Malhotra, M.D. | |||||
Insights From Neuroimaging to Guide Drug Choice and Development Carol A. Tamminga, M.D. | |||||
The Science of Subjective Tolerability: “Wellness” as a Treament Outcome Meera Narasimhan, M.D. | |||||
Recovery and Remission: Definitions, Dilemmas, and the Emergent Role of Peer Support Peter F. Buckley, M.D. | |||||
IS7. Bipolar Disorder: Creating a Consensus From Science to Public PolicySupported by Solvay Wyeth Pharmaceuticals
Treatment Considerations for Mania in Young Children Barbara Geller, M.D. | |||||
Treatment of Bipolar Disorder in U.S. Jails and Prisons Joseph R. Calabrese, M.D. | |||||
The Impact of Psychosocial Treatment on the Course and Prognosis of Bipolar Disorder Ellen Frank, Ph.D. | |||||
A Rational Approach for the Longitudinal Pharmacologic Management of Patients With Bipolar Disorder: An Argument for Changing Public Policy Mark H. Rapaport, M.D. | |||||
Alternative Pharmacologic Approaches to the Care of Bipolar Patients Alexander H. Fan, M.D. | |||||
IS8. Treatment-Resistant Depression: New Data, New ApproachesSupported by Cyberonics, Inc.
Definitions and Clinical Characteristics of Treatment-Resistant Depression David L. Dunner, M.D. | |||||
Treatment Resistance and Genes: The Biology Versus Pharmacology Enigma Francisco A. Moreno, M.D. | |||||
PET of Chronic Vagal Nerve Stimulation in Severe, Treatment-Resistant Depression Jose V. Pardo, M.D. | |||||
Augmentation Strategies for Patients With Difficult-to-Treat MDD Alicia R. Ruelaz, M.D. | |||||
Brain Stimulation Therapies for Treatment-Resistant Depression Linda L. Carpenter, M.D. ▪ | |||||
